<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537377</url>
  </required_header>
  <id_info>
    <org_study_id>VTX-801_CLN_001</org_study_id>
    <secondary_id>2020-000963-22</secondary_id>
    <nct_id>NCT04537377</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease</brief_title>
  <acronym>GATEWAY</acronym>
  <official_title>A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivet Therapeutics SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivet Therapeutics SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this clinical trial are to assess, for up to 5 years, the safety,&#xD;
      tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene&#xD;
      therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and&#xD;
      following background WD therapy withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability profile (including treatment-emergent adverse events (TEAE))</measure>
    <time_frame>at 1-Year post treatment</time_frame>
    <description>AEs will be summarized based on the date of onset for the event. Number of treatment-emergent AEs will be provided by SOC and PT, by dose cohort and overall.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free serum Cu</measure>
    <time_frame>at 1-Year post treatment</time_frame>
    <description>Free serum Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum Cu</measure>
    <time_frame>at 1-Year post treatment</time_frame>
    <description>Total serum Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary Cu</measure>
    <time_frame>at 1-Year post treatment</time_frame>
    <description>24-hour urinary Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ceruloplasmin activity (enzymatic assay)</measure>
    <time_frame>at 1-Year post treatment</time_frame>
    <description>Serum ceruloplasmin will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTX-801 Responder status</measure>
    <time_frame>At Week 12 and Week 36</time_frame>
    <description>The number of Responders and Insufficient-Responders will be summarized by dose cohort and planned visit, with response to treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Wilson's Disease</condition>
  <arm_group>
    <arm_group_label>VTX-801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VTX-801</intervention_name>
    <description>The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).&#xD;
After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels.</description>
    <arm_group_label>VTX-801</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged between 18 and 65 years&#xD;
&#xD;
          -  Patient diagnosed with WD, as historically established and documented by Leipzig score&#xD;
             ≥ 4, as per the 2012 EASL Clinical Practice Guidelines (EASL, 2012) and genetically&#xD;
             confirmed&#xD;
&#xD;
          -  Treated for WD according to international recommendations with no current evidence for&#xD;
             inadequate treatment (EASL, 2012; Roberts et al, 2008)&#xD;
&#xD;
          -  Stable WD for ≥ 1 year, defined as: (i) No significant change in neurologic&#xD;
             examination and in status of mood disorder, if present, as judged by a&#xD;
             physician-expert(s) in assessing neurological and psychiatric manifestations of WD and&#xD;
             (ii) Stable laboratory parameters used to assess copper metabolism including 24-hour&#xD;
             urinary copper, non-ceruloplasmin-bound copper (NCC), as well as liver enzymes,&#xD;
             hemoglobin, and white blood cell count&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  ALT level (mean of 2 measurements ≥ 1-week apart) &gt; ULN or either of the 2&#xD;
             measurements &gt; 1.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN in the absence of proven Gilbert's syndrome; in case of&#xD;
             Gilbert's syndrome, direct bilirubin &gt; ULN&#xD;
&#xD;
          -  INR &gt; ULN&#xD;
&#xD;
          -  Any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6&#xD;
             months (24 weeks) prior to screening/enrolment visit&#xD;
&#xD;
          -  Patient has moderate or severe renal impairment defined as eGFR CKD-EPI &lt; 60&#xD;
             mL/min/1.73 m2, or patient has nephritis or nephrotic syndrome&#xD;
&#xD;
          -  Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection&#xD;
&#xD;
          -  Any history or current evidence of hepatitis B infection&#xD;
&#xD;
          -  Any history of hepatitis C infection, unless previous viral RNA assays in two samples,&#xD;
             collected at least 6 months apart, are negative&#xD;
&#xD;
          -  Positive QuantiFERON®-TB Gold tuberculosis test result&#xD;
&#xD;
          -  Any concomitant disorder/condition - including hepatic disorders - or treatment&#xD;
             possibly interfering with the conduct or evaluation of the study, according to the&#xD;
             Investigator&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Body Mass Index ≥ 35 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonia Valero</last_name>
    <phone>+33 1 83 81 17 10</phone>
    <email>info@vivet-therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Dhaliwal</last_name>
      <phone>916-734-8696</phone>
      <email>sandhaliwal@UCDAVIS.EDU</email>
    </contact>
    <investigator>
      <last_name>Valentina Medici, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medecine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daksshi Hettiarachchi</last_name>
      <phone>203-737-5037</phone>
      <email>daksshi.hettiarachchi@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schilsky, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Page</last_name>
      <phone>734-998-9966</phone>
      <email>ashpage@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick Askari, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

